Aiming, Well, it looks like you'll be getting that buying opportunity in the 2s. The question now is how much info will Dr. Stoll be able to give us in the conf call. This excuse of not wanting to give the competition useful info seems lame to me, though the probable real reason (not wanting to irritate the FDA) has merit. Still, I don't see what harm a brief overview of the dosing restrictions would do. Not giving any details at all will only encourage more selling, and at a time when we need to raise money. It's frustrating to have such a promising technology, but a chronic lack of funds to develop it.
News 
Market Data 
Discover 
AI
